معدل الاستجابة عقب علاج ألبومين-مقيد باكليتاكسيل زائد جيمسيتابين زائد سيسبلاتين بين مرضى سرطان البنكرياس المتقدم

درس جيمسون وآخرون (الخميس) هذا السؤال.

www.synapsesocial.com/papers/69dd67d280eea7d3f699c92a — DOI: https://doi.org/10.1001/jamaoncol.2019.3394

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers· 2019 · 472 citations
2. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial· 2018 · 69 citations
3. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer· 2011 · 7,698 citations
4. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,254 citations
5. A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.· 2017 · 23 citations